Valrubicin

戊柔比星

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameValrubicin
Drug Alias NamevalrubicinavalrubicinevalrubicinumValstarValtaxin +[7] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Anthracycline antibioticsSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsUrinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ
Global Approved IndicationsUrinary Bladder NeoplasmsCarcinoma in Situ
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1998/09/25
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesEndo International Plc
China Registration ClassN/A

Develop Information

Active CompaniesEndo Operations Ltd
Inactive CompaniesH Lee Moffitt Cancer Center & Research InstituteNational Cancer InstituteEndo Pharmaceuticals Inc +[4] 
Active IndicationsUrinary Bladder NeoplasmsCarcinoma in Situ
Inactive IndicationsCarcinoma, Transitional Cell

Other Information

ATC CodeL01DB09
Related LinksWikipediaDrugBankKEGG